StockData
MGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Metagenomi Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$0.81+0.03 (+3.55%)

Close on Oct 19, 2026

Market cap
$30.57M
P/E (TTM)
–
Dividend yield
–

Metagenomi Therapeutics, Inc. revenue by segment

AnnualQuarterlyTTM

No segment breakdown reported

Metagenomi Therapeutics does not break out revenue by segment, region or product in the tagged data of its filings for this period type.